News & Updates
Filter by Specialty:
Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients
Treatment with dupilumab increases the levels of bone alkaline phosphatase (BALP), a marker of bone mineralization, in paediatric patients with moderate-to-severe atopic dermatitis (AD), regardless of asthma comorbidity, reports a study presented at ACAAI 2023.
Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients
17 Nov 2023
Biologic therapy improves life quality of asthmatic children
Treatment with biologic agents results in significant improvements in both function and quality of life among paediatric patients with moderate-to-severe asthma, according to a recent study presented at ACAAI 2023.
Biologic therapy improves life quality of asthmatic children
17 Nov 2023
RNAi agent RG6346 shows promise for treatment of chronic HBV infection
A first-in-human randomized, phase I study has provided evidence to support the clinical development of RG6346 as a therapeutic regimen for chronic hepatitis B virus (HBV) infection (CHB), with the goal of sustained hepatitis B surface antigen (HBsAg) loss in CHB patients.
RNAi agent RG6346 shows promise for treatment of chronic HBV infection
17 Nov 2023
Topical diclofenac prevents HFS in capecitabine-treated cancer patients
Patients with breast or gastrointestinal (GI) cancer who are being treated with capecitabine monotherapy may benefit from using topical diclofenac gel to prevent or reduce the incidence of hand-foot syndrome (HFS), a common side effect of some chemotherapy drugs, reports a recent study presented at ESMO 2023.
Topical diclofenac prevents HFS in capecitabine-treated cancer patients
15 Nov 2023
Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer
First-line treatment with TST001 (osemitamab) in combination with capecitabine and oxaliplatin (CAPOX) is safe and well tolerated in patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer, according to a study presented at ESMO 2023.